Publications by authors named "Kristina Beeler"
Article Synopsis
- Circulating proteomes can reveal the body's response to diseases like COVID-19 and treatments like tocilizumab, which is used to mitigate severe symptoms.
- In a study involving 28 hospitalized COVID-19 patients treated with tocilizumab, researchers collected serum samples to analyze changes in protein levels before and after treatment and assessed patient outcomes for 30 days.
- Findings indicated that specific proteins related to the complement system and Fc-epsilon receptor signaling could predict treatment success and mortality, where high complement activation linked to worse outcomes and certain signaling pathways showed lower mortality rates.
Article Synopsis
- * Using a combination of proteomic and transcriptomic analyses on tissue samples from 22 patients, they found that certain protein and gene signatures were linked to poorer outcomes, specifically in progression-free survival (PFS) and overall survival (OS).
- * Patients with low-risk signatures exhibited significantly worse treatment responses, showing that those with higher expression levels of the identified biomarkers had better PFS and OS results, highlighting the importance of these combined biomarkers for predicting patient outcomes.
Cancers are immunologically heterogeneous. A range of immunotherapies target abnormal tumor immunity via different mechanisms of actions (MOAs), particularly various tumor-infiltrate leukocytes (TILs). We modeled loss of function (LOF) in four common anti-PD-1 antibody-responsive syngeneic tumors, MC38, Hepa1-6, CT-26 and EMT-6, by systematical depleting a series of TIL lineages to explore the mechanisms of tumor immunity and treatment.
View Article and Find Full Text PDFCyclin-dependent-kinases (CDKs) are members of the serine/threonine kinase family and are highly regulated by cyclins, a family of regulatory subunits that bind to CDKs. CDK9 represents one of the most studied examples of these transcriptional CDKs. CDK9 forms a heterodimeric complex with its regulatory subunit cyclins T1, T2 and K to form the positive transcription elongation factor b (P-TEFb).
View Article and Find Full Text PDF